| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
p53-MDM2-IN-1 targets the p53-MDM2/X protein-protein interaction (PPI). The compound is an inhibitor of this interaction, with a Ki value of 23.35 µM. By disrupting the binding between p53 and its negative regulator MDM2, the compound stabilizes and activates p53, a key tumor suppressor protein. This leads to the induction of p53-dependent anti-tumor activities, including cell cycle arrest and apoptosis.
|
|---|---|
| ln Vitro |
In cell-free biochemical assays, p53-MDM2-IN-1 inhibits the p53-MDM2/X protein-protein interaction with a Ki value of 23.35 µM. This activity demonstrates the compound's direct binding and disruption of the MDM2-p53 complex. The compound's inhibitory activity is typically measured using fluorescence polarization, AlphaScreen, or ELISA-based binding assays. The compound is a synthetic small molecule characterized by a trans (D-) configuration.
|
| ln Vivo |
In cell-based assays, p53-MDM2-IN-1 activates p53 by disrupting the MDM2-p53 interaction, leading to the induction of p53-dependent anti-tumor activities. The compound can be used for anti-tumor research. By stabilizing p53, the compound promotes cell cycle arrest and apoptosis in cancer cells. The compound's effects on p53 target gene expression and cell viability are evaluated in cancer cell lines.
|
| Enzyme Assay |
The cell-free assay for p53-MDM2-IN-1 involves measuring the inhibition of the p53-MDM2/X protein-protein interaction. This is typically performed using fluorescence polarization or AlphaScreen technology. The assay involves incubating purified MDM2 protein with a fluorescently labeled p53 peptide and the compound at various concentrations. The Ki value of 23.35 µM is determined from competitive binding curves. The compound's activity can also be assessed using ELISA-based binding assays.
|
| Cell Assay |
Cell-based assays for p53-MDM2-IN-1 involve culturing cancer cell lines with wild-type p53 and treating them with the compound at concentrations ranging from 0.1 to 100 µM. Cells are incubated for 24-72 hours, and p53 activation is assessed by measuring the expression of p53 target genes such as p21 and PUMA by qRT-PCR or Western blotting. Cell cycle analysis is performed by flow cytometry, and apoptosis is evaluated by Annexin V staining or caspase activity assays. Cell viability is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
In animal models, p53-MDM2-IN-1 has been evaluated for its anti-tumor activity. Typical studies involve administration of the compound to tumor-bearing mice via intraperitoneal or oral routes at doses determined from toxicity studies. Tumor volumes are measured, and tissues are collected for analysis of p53 activation, cell cycle arrest, and apoptosis. The compound's ability to inhibit tumor growth is assessed, and biomarkers of p53 pathway activation are measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of p53-MDM2-IN-1 have not been extensively reported. As a small molecule with a molecular weight of 421.88 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is slightly soluble in DMSO. Storage conditions are 4°C, protect from light. Further pharmacokinetic studies would be required to determine plasma half-life, clearance, and metabolic pathways.
|
| Toxicity/Toxicokinetics |
p53-MDM2-IN-1 is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent. As a p53 activator, the compound may have effects on normal cells as well as cancer cells. Standard toxicity studies in rodents would be required to determine the maximum tolerated dose, target organ toxicity, and safety profile if therapeutic development is pursued.
|
| References | |
| Additional Infomation |
p53-MDM2-IN-1 is a research-grade compound supplied for anti-tumor research. It is not an approved pharmaceutical and has no clinical trial history. The compound is typically stored at 4°C, protect from light. Purity specifications generally exceed 98%. It is a synthetic compound characterized by a trans (D-) configuration. This product is intended for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C23H20CLN3O3
|
|---|---|
| Molecular Weight |
421.88
|
| Exact Mass |
421.119
|
| CAS # |
381717-91-5
|
| PubChem CID |
6049382
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
686.1±55.0 °C at 760 mmHg
|
| Flash Point |
368.7±31.5 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.659
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
669
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)/C(=C\2/C(N(C(=O)C2=O)CCCN3C=CN=C3)C4=CC=C(C=C4)Cl)/O
|
| InChi Key |
JBSITHXZPKMWGY-XUTLUUPISA-N
|
| InChi Code |
InChI=1S/C23H20ClN3O3/c24-18-9-7-16(8-10-18)20-19(21(28)17-5-2-1-3-6-17)22(29)23(30)27(20)13-4-12-26-14-11-25-15-26/h1-3,5-11,14-15,20,28H,4,12-13H2/b21-19+
|
| Chemical Name |
(4E)-5-(4-chlorophenyl)-4-[hydroxy(phenyl)methylidene]-1-(3-imidazol-1-ylpropyl)pyrrolidine-2,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3703 mL | 11.8517 mL | 23.7034 mL | |
| 5 mM | 0.4741 mL | 2.3703 mL | 4.7407 mL | |
| 10 mM | 0.2370 mL | 1.1852 mL | 2.3703 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
